Eversense 365 is Widely Available by Insurance for Patients Taking Insulin
Overview of coverage, coding and billing information for Inserters to help get your patients started on Eversense.
For patients with Commercial Insurance
Eversense 365 is covered by most commercial health plans.
Eligible patients may pay as little as $199 for a full year with the Eversense PASS Program†
For patients on Medicare
Eversense 365 is available to patients with Medicare.1
Send patient referrals to Ascensia Diabetes Care by:
1. Parachute Health, or
2. Fax Patient Information Form, Certificate of Medical Necessity, Chart Notes and Insurance Info
Download for information on:
Please complete your contact details and an Ascensia Diabetes Care representative will follow up with you shortly to discuss your inquiry.
Please provide your direct contact details to prevent any delays in response.
*Indicates required field.
We have receieved your message.
A general error occurred. Please try again later.
* There is no glucose data generated when the transmitter is removed
† Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. See website (bit.ly/EversensePass) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. There is a maximum payment of $2,500 per transaction for the program.. There may be instances in which patient out-of-pocket costs exceed what is detailed in the offer. Eversense E3 is not eligible for the PASS Program.
1. Speak to an Eversense Expert for more information on Medicare coverage.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0064